Precision for Medicine Expands Services in Europe, Announces Next Generation Biomarker Data Management and Translational Informatics Platform
ADDITION OF GENEVA-BASED TEAM COMPLEMENTS U.S. EXPERTS;
QuartzBio? RELEASE ACCELERATES BIOMARKER DATA MANAGEMENT
AND TRANSLATIONAL INFORMATICS CAPABILITIES
Bethesda, MD and Geneva, Switzerland – January 9, 2018 – Precision for Medicine, part of Precision Medicine Group, today announced it is expanding its biomarker data management and translational informatics services into Europe. The addition of a Geneva, Switzerland–based team of experts complements Precision’s US offerings to provide clients with truly global translational research services. The Geneva team also gives Precision another European operational base, continuing Precision’s active international expansion.
Precision Medicine Group Lands Major New Investment
BERKSHIRE PARTNERS AND TPG GROWTH CO-LEAD $275 MILLION INVESTMENT AS THE COMPANY POSITIONS FOR THE NEXT PHASE OF GROWTH
BETHESDA, MD — December 19, 2017 — Precision Medicine Group (PMG) announced today that it has reached an agreement for a $275 million investment that positions the company for the next phase of growth. (more…)
Precision Xtract Named an Industry Innovator by PM360
Precision Xtract is proud to be named one of the year’s most innovative developments by industry insider PM360. (more…)
Precision’s Snider Interviewed by AJMC Regarding New CAR-T Societal Value Study
A new Precision Health Economics-authored study on the societal value of CAR-T therapy is generating a significant level of interest within the scientific community. (more…)
Precision Oncology’s Messerschmidt Video Interview: Promising Times in Rare Cancers
Rare Disease Report interviews Chief Medical Officer Gerald Messerschmidt while at the American Society of Hematology Annual Meeting. (more…)